Cantor Fitzgerald Comments On Neurocrine Biosciences Following Phase 2 Data On Co.'s Luvadaxistat: Says, 'No Positive on Negative Symptoms, but Signal in Cogniton Keeps luva' in the Game'; Maintains Overweight Rating, $128 Price Target